Mintz represented Sixth Street in connection with a $1.3 billion financing – alongside co-investor Blackstone Credit & Insurance – in support of the combination of Paratek Pharmaceuticals (Paratek) and Radius Health (Radius), creating a scaled, multi‑product specialty pharmaceutical company backed by B‑FLEXION Life Sciences.  
 
The combination brings together the commercial portfolios of Paratek, including  NUZYRA® and XHANCE®, and Radius, including TYMLOS®, to create a diversified specialty pharmaceutical portfolio expected to generate nearly $1 billion in annual revenue in 2026, while further advancing Paratek’s and B‑FLEXION’s strategy of building an integrated pharmaceutical platform focused on high‑need, targeted therapeutic areas.

The Mintz team was led by Richard Gervase, Member and Chair of the firm’s Royalty & Revenue Interest Financing Transactions Group, with support from Tali Tuchin (Corporate), Eric Blythe (Bankruptcy & Restructuring), Joanne Hawana (Regulatory), and Associates Peter Hecker (Intellectual Property), Christine Pemberton (Intellectual Property), and Joshua Li (Intellectual Property) 

Read Sixth Street’s press release here, Blackstone’s press release here, and Paratek’s press release here. 

About Sixth Street 
Sixth Street is a global investment firm with over $125 billion in assets under management and committed capital. Sixth Street uses its long-term flexible capital, data-enabled capabilities, and One Team culture to develop themes and offer solutions to companies across all stages of growth. Sixth Street Healthcare and Life Sciences invests thematically throughout the healthcare ecosystem, providing flexible capital solutions to companies addressing our most pressing healthcare challenges and improving patient outcomes. Investments in the sector include Beam Therapeutics, Apellis Pharmaceuticals, Arrowhead Pharmaceuticals, Arsenal Biosciences, Biohaven, Blueprint Medicines, Caris Life Sciences, Chroma Medicine, ConcertAI, Datavant, Essential Pharma, Immunogen, Ironwood, Mammoth Biosciences, and Velocity Clinical Research, among many others. Founded in 2009, Sixth Street has more than 700 team members including over 300 investment professionals around the world.
 
About Mintz 
Mintz is a leading 600+ attorney law firm with deep experience in the life sciences industry. We work with leading industry investors and underwriters in innovative financings and offerings, help entrepreneurs launch and protect great ideas, facilitate funding opportunities, and counsel emerging as well as established and public companies in all aspects of their businesses, including regulatory approvals and compliance. To learn more about our team, please visit www.mintz.com.